



HAL
open science

Cardiovascular Disease in the Elderly: Proceedings of the European Society of Cardiology-Cardiovascular Round Table

Maddalena Lettino, Julia Mascherbauer, Matias Nordaby, André Ziegler, Jean-Philippe Collet, Geneviève Derumeaux, Stefan H Hohnloser, Christophe Leclercq, Deirdre E O’neill, Frank Visseren, et al.

► **To cite this version:**

Maddalena Lettino, Julia Mascherbauer, Matias Nordaby, André Ziegler, Jean-Philippe Collet, et al.. Cardiovascular Disease in the Elderly: Proceedings of the European Society of Cardiology-Cardiovascular Round Table. European Journal of Preventive Cardiology, 2022, 10.1093/eur-jpc/zvac033 . hal-03593788

HAL Id: hal-03593788

<https://hal.science/hal-03593788>

Submitted on 1 Apr 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 ESC CRT on CVD in the elderly
2
3
4

5 **Cardiovascular Disease in the Elderly: Proceedings of the European** 6 **Society of Cardiology – Cardiovascular Round Table** 7 8 9

10 **Authors**

11 Maddalena Lettino¹, Julia Mascherbauer², Matias Nordaby³, André Ziegler⁴, Jean-Philippe Collet⁵,
12 Geneviève Derumeaux⁶, Stefan H. Hohnloser⁷, Christophe Leclercq⁸, Deirdre E. O'Neill⁹, Frank
13 Visseren¹⁰, Franz Weidinger¹¹, Isabelle Richard-Lordereau¹²
14

15 **Institution(s) where work performed**

16 CRT Online Plenary Meeting
17
18

19 **Affiliations**

20 ¹Director of Clinical Cardiology, Cardiovascular Department, San Gerardo Hospital of Monza, Monza,
21 Italy;

22 ²Karl Landsteiner University of Health Sciences, University Hospital St. Pölten, Krems, Austria;

23 ³Global Head of Medical Affairs for Heart Failure, Boehringer-Ingelheim, Ingelheim am Rhein,
24 Germany;

25 ⁴Global Clinical Leader, Cardiovascular Diseases, Roche Diagnostics, Rotkreuz, Switzerland;

26 ⁵ACTION Group, www.action-groupe.org, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-
27 Salpêtrière (AP-HP), Institut de Cardiologie, Paris, France

28 ⁶Chief, Physiology Department. Henri Mondor Hospital (APHP), FHU SENEK, Créteil, France, and
29 Mondor Biomedical Research Institute (IMRB), UPEC, Créteil, France;

30 ⁷Professor of Cardiology, J.W. Goethe university, Frankfurt, Germany, and Senior Researcher, Center of
31 Thrombosis and Hemostasis, University of Mainz, Mainz, Germany;

32 ⁸Professor of Cardiology and Head of the Department of Cardiology, Department of Cardiology, CHU
33 Rennes and Inserm, LTSI, University of Rennes, Rennes, France;

34 ⁹Associate Professor of Cardiology, University of Alberta Hospital, Edmonton, Canada, and
35 Mazankowski Heart Institute, Edmonton, Canada;

36 ¹⁰Head, Department of Vascular Medicine, University Medical Center, Utrecht, The Netherlands;

37 ¹¹Head, 2nd Medical Dept. with Cardiology and Intensive Care Medicine, Hospital Rudolfstiftung,
38 Vienna, Austria

39 ¹²Executive Medical Director and Therapeutic Area Head of General Medicine Europe, Amgen Europe,
40 Rotkreuz ZG, Switzerland;
41

42 **Corresponding author**

43 Dr. Maddalena Lettino

44 Via Ceradini 3, 20129,

45 Milano, Italy

46 Tel: +39 339 2241194

47 Fax: no fax number available

48 Email: maddalena.lettino@hotmail.it
49

50 **Word count:** 4,645 (excluding references and abstract); Abstract 211
51
52
53
54

55 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For
56 permissions, please email: journals.permissions@oup.com.
57
58
59

4 **Abstract**
5
6

7 The growing elderly population worldwide represents a major challenge for caregivers,
8 healthcare providers, and society. Older patients have a higher prevalence of cardiovascular (CV)
9 disease, high rates of CV risk factors, and multiple age-related comorbidities. Although
10 prevention and management strategies have been shown to be effective in older people they
11 continue to be under-used, and under-studied. In addition to hard endpoints, frailty, cognitive
12 impairments, and patients' re-assessment of important outcomes (e.g., quality of life versus
13 longevity) are important aspects for older patients and emphasize the need to include a
14 substantial proportion of older patients in CV clinical trials. To complement the often skewed
15 age distribution in clinical trials, greater emphasis should be placed on real-world studies to
16 assess longer-term outcomes, especially safety and quality of life outcomes. In the complex
17 environment of the older patient, a multidisciplinary care team approach with the involvement of
18 the individual patient in decision-making process can help optimize prevention and management
19 strategies. This paper aims to demonstrate the growing burden of ageing in real life and
20 illustrates the need to continue primary prevention to address cardiovascular risk factors. It
21 summarizes factors to consider when choosing pharmacological and interventional treatments in
22 the elderly, and the need to consider quality of life and patient priorities when making decisions.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Keywords:** risk assessment, older people, primary prevention, antiplatelet, anticoagulant, coronary
48 revascularization
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Introduction

Globally, the population is ageing, with older people becoming a proportionally larger share of the total population.^{1,2} In Europe in 2017, more than 20% of the population was age ≥ 60 years, and this is projected to increase to 35% by 2050. The incidence of cardiovascular disease (CVD) increases with age from about 40% in adults aged 40-59 years, to 75% in those 60-79 years, and 86% in those >80 years.³ This has been linked to several factors such as increased oxidative stress, inflammation, apoptosis and overall vascular and myocardial deterioration associated with ageing, as well as to a higher risk for other morbid conditions including frailty, obesity, and diabetes.³

While ageing is often measured chronologically (i.e., the number of years since birth), this does not reflect the distribution of functional capacities, health, and productivity within the older population.^{4 5} Clinical trials have a need to “categorise” patient populations for analyses, and often use arbitrary cut-offs of over age 65 years, 70 years, 75 years, etc. However, a review of 20 guidelines found that all used the term elderly, but 17 did not define the term in anyway.⁶ The 2021 ESC Guidelines on CV prevention, and the Systemic Coronary Risk Estimation 2-Older Persons (SCORE2-OP) risk prediction tool used a cut-off of 70 years of age.^{7, 8} Clinically when making management decisions, elderly or older age should be based less on chronological age and more on defining the risk and outcomes for an individual patient.

This article is the product of presentations and discussions during a virtual Cardiovascular Round Table (CRT) workshop organised in May 2021 by the European Society of Cardiology (ESC). It aims to demonstrate the need to continue primary prevention for cardiovascular risk factors, to summarise important factors when choosing treatments for older patients, and the need to consider quality of life and patient priorities when making decisions.

CV risk assessment in older people: Are we over treating or under treating?

Factors to consider when assessing risk of CVD in older people

In older people, the lifetime benefit from CVD risk-factor treatment should consider absolute CV risk, life expectancy, competing (non-CV) risks, and efficacy and safety data from randomised controlled trials (RCT) (Figure 1).^{7,9} Moreover, management decisions should be patient-centric and consider patient preferences, frailty, comorbidities, and polypharmacy.

Risk assessment tools for older people

While age is a strong predictor of risk, the PROSPER trial demonstrated that age alone does not automatically put an individual at high risk, especially in the primary prevention setting.¹⁰ Therefore, risk prediction tools can help identify patients at higher CV risk who may potentially benefit from treatment. Tools designed for the general population can be inaccurate in older people.^{7,11} The relationship between many risk factors and CVD decreases with age, and competing risks become increasingly important.⁷ In addition, older patients are generally at higher risk of adverse drug events, so it is important to identify those individuals who benefit from preventive treatment.

In 2021, the SCORE2-OP tool was developed and validated to estimate 5- and 10-year CVD risks of both fatal and nonfatal CVD events (myocardial infarction, stroke), in adults aged ≥ 70 years.⁷ The sex-specific scores include age, smoking status, systolic blood pressure, and high-density lipoprotein cholesterol and are adjusted for competing risks. Therefore, the threshold levels in different risk categories are higher in older age groups, in order to avoid overtreatment in older persons. The decision to initiate preventive therapy should consider that

4 both benefits and risks of treatments are impacted by age, and therefore, should be made on an
5 individual basis with the patient.⁸ In older people the focus should be on the lifetime benefit of
6
7 treating risk factors rather than 10-year CVD risk.⁹ Risk calculators are available online at
8
9 www.u-prevent.com.¹²
10
11
12
13
14

15 **Primary prevention strategies in older people: Is it ever too late?** 16

17
18 Given that CVD begins at a young age, primordial and primary prevention strategies to
19 address risk factors should start early to prevent CV events at older age.¹³ While, data show that
20 it is never too late to initiate risk factor management strategies, the goal of preventative medicine
21 in older adults is somewhat different; focusing not only on reduction of morbidity and mortality,
22 but more significantly on maintenance of function and preservation of quality of life. The 2021
23 ESC guidelines on CVD prevention include a section focused on older adults aged ≥ 70 years,
24 acknowledging the importance of primary prevention throughout the lifespan.⁸ This should be
25 delivered in an individualized and patient-centred manner, focusing on outcomes important to
26 the patient, and using interventions with the best evidence and least risk to their day-to-day
27 function.
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **General considerations when using pharmacotherapy in older people:** In general,
43 when addressing primary prevention in older adults, the risk of CVD, which is higher by virtue
44 of age, needs to be balanced with the evidence for potential benefit of a medication in an older
45 population, as well as the potential risk of that medication in that individual patient. When doing
46 so, it is important to keep in mind that a number of factors can all lead to well-intentioned,
47 evidence-based medications being poorly tolerated by the older adult or even resulting in harm.
48 Factors that should be considered include changes in pharmacokinetics and pharmacodynamics
49 that occur with age, increased risk and susceptibility to disease-drug interactions, drug-drug
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4 interactions, and adverse events with polypharmacy in older adults, and varied and unexpected
5 clinical response to medications.^{14, 15} For example, the prescription of a statin for a high-risk
6 individual could lead to myalgias that prevent performance of activities of daily living, or an
7 antihypertensive medication in an individual with an untreated blood pressure of 160/90 mmHg,
8 may result in orthostatic hypotension that can result in injurious falls.^{14, 15} It is important to
9 engage in shared decision-making and practice patient-centred care, providing the best estimate
10 of risks and benefits based on the evidence and discussing the patient's values, preferences, and
11 risk tolerance. Clinicians and patients may inadvertently have opposing goals, with patients
12 being more concerned about symptoms, functional and cognitive status, and quality of life, and
13 clinicians being more interested in preventing major cardiac adverse events or reducing mortality
14 rate.^{14, 15} Discussing an individual's values, and when in keeping with their preferences,
15 addressing non-pharmacologic risk reduction, such smoking cessation, diet and exercise and
16 when needed, starting pharmacotherapy at low doses and titrating slowly, can help ensure the
17 best possible outcome in this vulnerable patient population.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

38 In older people, the ability to follow lifestyle or pharmacological strategies can be
39 impacted by cognitive and emotional factors.⁸ Cognitive decline shares many risk factors with
40 CVD, including high cholesterol, and high blood pressure, obesity, diabetes, physical inactivity,
41 smoking, and poor diet.¹⁶ In addition, higher levels of cardiac troponin T have been associated
42 with cognitive decline in older adults independent of CVD.¹⁷ The importance of primary
43 prevention is underscored by the fact that CV events have been associated with accelerated
44 cognitive decline over time.¹⁸
45
46
47
48
49
50
51
52
53
54

55 **Hypertension:** The prevalence of hypertension in older patients is very high, for
56 example, in the U.S. the prevalence in individuals 20-44 years was reported to be 28%,
57
58
59
60
61
62
63
64
65

1
2
3
4 increasing to 77% in those ≥ 65 .¹⁹ Multiple RCTs in older people have demonstrated the benefits
5
6 of blood pressure lowering in both fit and frail people, with the greatest absolute benefit being
7
8 seen in those 75-80 years of age (Table 1).²⁰⁻²⁵ However, this benefit is not without some degree
9
10 of risk, with estimations based on US population data suggesting intensive blood pressuring
11
12 lowering, such as that in the SPRINT trial, would result in >56,000 episodes of hypotension,
13
14 >34,000 episodes of syncope and nearly 89,000 episodes of acute kidney injury annually.^{23, 26}
15
16 Therefore, universal implementation of intensive blood pressure lowering has great potential
17
18 benefit, alongside potential detrimental consequences.
19
20
21
22

23
24 The older adult population is very heterogeneous, with large variation in function, frailty
25
26 and independence, necessitating a person-centred, rather than a “one-size fits all” approach to
27
28 balancing the risks and benefits.²⁷ While older adults with preserved function should often be
29
30 treated similar to younger adults, those with advanced frailty and functional dependence should
31
32 have their hypertension management reassessed, with consideration of deprescribing and blood
33
34 pressure leniency to avoid further functional impairment from adverse effects.^{15, 28-30} Clinical
35
36 decision making for older adults in between these two spectrums is most challenging, requiring a
37
38 tailored approach considering comorbidities, life expectancy, function, frailty, as well as patient
39
40 preferences in a process of shared decision-making. The 2018 ESC/European Society of
41
42 Hypertension guidelines recommend offering antihypertensive treatment to older adults (>65
43
44 years, including individuals >80 years with very high systolic blood pressure), taking into
45
46 account factors such as comorbidities, polypharmacy, frailty and dependence, and not viewing
47
48 age alone as a barrier to the treatment of hypertension.³¹ In addition, the ESC CVD prevention
49
50 guidelines recommend lowering blood pressure to <140/90 mmHg, and to consider a lower
51
52 systolic blood pressure target of 130 mmHg in those ≥ 70 years, if tolerated.⁸
53
54
55
56
57
58
59
60
61
62
63
64
65

Hyperlipidaemia: The prevalence of hyperlipidaemia is also more frequent in older people. In a European study, hyperlipidaemia was present in 76% in older people (mean age 69 years) compared to 41% in younger (mean age 29 years) people.³² While evidence supports the benefit of lipid-lowering therapy in older adults with known vascular disease, the evidence for primary prevention in older adults is less clear.^{33, 34} A meta-analysis of 8 primary prevention trials in people ≥ 65 years, at high CV risk, found a significant reduction in the risk of MI and stroke (39.4% and 23.8%, respectively) with statins versus placebo (Table 1).³⁵ Primary prevention studies in people >75 years are more limited however, and it is difficult to extrapolate data from younger age groups to this population.^{33, 35, 36} A meta-analysis of 28 statin trials found a significant reduction in major cardiovascular events (MACE) in all age groups, with a 13% reduction in events per 1.0 mmol/L reduction in LDL cholesterol in patients over 75 years old, however only 8% of participants were in this age group.³³

While older adults are intrinsically vulnerable to CVD, thereby increasing the potential benefit of statin, they are also susceptible to frailty, sarcopenia, polypharmacy, and multi-morbidity, increasing the risk of statin-related adverse effects and compounding the functional burden of such adverse effects. Additionally, statins have a rather short time-to-harm, with a relatively long time-to-benefit of at least 2-2.5 years, making life expectancy very pertinent when prescribing primary prevention statin.^{37, 38} It is unlikely that benefit would outweigh risk in those with a limited life expectancy, however many older adults have an anticipated prognosis of >2.5 years, making shared decision-making and consideration of individual patient's goals and values essential. Current data to inform decisions on primary prevention cholesterol management in older adults are limited, but two large randomized controlled trials are underway. STAREE and PREVENTABLE are both designed to assess the role of primary prevention statins in patients

≥70-75 years and include outcome measures relevant to older adults, such as independence and disability.^{39, 40}

The ESC CVD prevention guidelines provide a class IIb recommendation (may be considered) for initiation of statins for primary prevention in older adults aged ≥70 if at high 10-year CVD risk, when assessed using SCORE2-OP, a risk score validated to estimate 5- and 10-year CVD risk in older adults aged ≥70 years.^{7, 8} However, the decision to use statin therapy for primary prevention in older adults should be individualised, based on frailty, estimated life expectancy, time to benefit, comorbidities and patient preference.

Diabetes: The prevalence of type 2 diabetes mellitus increases with age.⁴¹ Metformin has been shown to reduce the risks of MI, CV death, and stroke in overweight patients with diabetes compared to conventional therapy (Table 1),⁴² and the both the 2019 ESC guidelines on diabetes and 2021 ESC CVD prevention guidelines recommend it as first-line therapy for primary prevention in patients with diabetes.^{8, 43} Two newer classes of medications have been found to lower blood glucose and reduce CVD events in those at high risk: SGLT-2 inhibitors^{44, 45} and GLP-1 receptor agonists.⁴⁶⁻⁴⁸ Post hoc analyses of pivotal trials show that these agents have similar effect on CV outcomes across age categories including those ≥75 years (SGLT-2 inhibitors)^{44, 45} and those ≥65 years (GLP-1 receptor agonists).⁴⁶⁻⁴⁸ ESC guidelines recommend these agents for primary prevention in patients with DM and CKD, and consideration of their use in those at high or very high CV risk.^{8, 43}

Aspirin: The evidence for use of aspirin in those with vascular disease (secondary prevention) is unequivocal. However, three more recent randomized controlled trials (ARRIVE, ASPREE and ASCEND) have led to contention about its role in primary prevention (Table 1).⁴⁹⁻⁵² While two of these trials were not specific to an older adult population, the ASPREE trial

randomized nearly 20,000 patients aged 70 years and above, without known CVD, to aspirin or placebo.⁵² After 4.7 years of follow up, the rate of CVD was unchanged (HR 0.95, 95% CI 0.83-1.08) but the rate of major bleeding was increased (HR 1.38, 95% CI 1.18-1.62) with aspirin compared to placebo in these older adults. A 2019 meta-analysis found no reduction in CV mortality with aspirin, but did show a lower risk of non-fatal myocardial infarction (RR 0.82, 95% CI 0.72-0.94) and stroke (RR 0.87, 95% CI 0.79-0.95), with a higher risk of major bleeding (RR 1.5, 95% CI 1.33 to 1.69), intracranial bleeding (RR 1.32, 95% CI 1.12-1.55) and major gastrointestinal bleeding (RR 1.52, 95% CI 1.34-1.73); with a number needed to harm of 222 for major bleeding and a number needed to treat of 357 to prevent one myocardial infarction.⁵³ The use of aspirin for primary prevention in selected patients at low bleeding risk and high or very-high CV risk remains controversial. However, overall, in the majority of older adults, the increased risk of bleeding appears to outweigh the CV primary prevention benefit, with many national and international guidelines downgrading or eliminating their recommendation for aspirin altogether in older adults.^{14, 54, 55} The 2021 ESC CVD prevention guidelines recommend making decisions in healthy individuals <70 years of age with (very) high CVD risk, on a case-by-case basis, with consideration of both ischaemic and bleeding risks.⁸ The risk of bleeding may be even more important in older patients, and any consideration of use for primary prevention should be discussed with the patient.^{56, 57}

Smoking is a known major cause of CVD, with 1 in 10 CV deaths worldwide being attributable to smoking.⁵⁸ Tobacco cessation has been shown to reduce CV risk even among people ≥ 60 years (Table 1).⁵⁹ Excess CV risk decreases with time since tobacco cessation, with benefits accruing within <5 years of quitting.^{59, 60} The ESC CV prevention guidelines recommend that clinicians encourage all smokers to quit, including those ≥ 70 years.⁸

Diet: Dietary modifications have been shown to lower the risk of CV events (Table 1).⁶¹,
⁶² In the PREDIMED RCT in people 55-80 years at high CV risk, a modified Mediterranean diet was associated with a 28-30% reduction in MACE over a median 5-year follow-up.⁶¹ Similarly, in the EPIC, multicentre cohort study in people ≥ 60 years without CVD, a modified Mediterranean diet was associated with a significantly longer life expectancy, with benefits increasing with increasing adherence to the diet.⁶² The ESC CVD prevention guidelines focus on the importance of maintaining a more plant-based diet, low in saturated fat, high in whole grains, fruit, vegetables, nuts and fish, while reducing red meat, alcohol and sugar-sweetened beverages.⁸ These lifestyle recommendations are applicable to all age groups.

Currently, there is insufficient evidence of benefit of vitamin C, D, or E in prevention of CVD.⁶³⁻⁶⁶ Evidence for omega-3 fatty acid supplementation is conflicting. A 2020 Cochrane review suggested little to no effect of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on mortality or CV health.⁶⁷ In a more recent meta-analysis (2021), EPA monotherapy was associated with a reduction in cardiovascular mortality, non-fatal myocardial infarction, coronary heart disease events, MACE, and revascularization.⁶⁸ While this evidence is not specific to older patients, it suggests that omega-3 fatty acid supplementation, specifically EPA, may be useful for prevention of CVD, however, there was an increased risk of AF and total bleeding events.

Although the risk associated with other less proven vitamin supplementation is low, it is important to remember that many older adults already struggle with polypharmacy and pill burden. Therefore, taking pills which are unlikely to provide benefit can result in worsening lack of appetite due to the number of pills ingested, as well as potential for medication non-adherence related to increased pill burden.

Exercise: Multiple observational studies have demonstrated the benefits of exercise for primary prevention of CVD (Table 1).⁶⁹⁻⁷² The Honolulu Heart Program, a cohort study in men aged 71-93 years, found that those who walked ≥ 1.5 miles/day had a 50% lower risk of CVD versus those who walked < 0.25 miles/day ($p < 0.01$).⁶⁹ In the Zutphen Elderly Study in men aged 64-84 years, self-reported physical activity proportionally decreased the risk of all cause (23%) and CVD (30%) mortality with increasing levels of activity.⁷⁰ Furthermore, maintaining activity levels, or engaging in small increases in the frequency of physical activity (even 1-2 times/week) have been associated with significantly reduced risk for total CVD among older people aged ≥ 60 years.⁷¹

Individuals of all ages can benefit from implementation of a safe, tailored exercise routine.^{14, 73} While moderate-to-vigorous activity is advised in the ESC CVD prevention guidelines, baseline fitness should be considered.⁸ Even frail older adults can benefit by moving from an inactive state to performing any physical activity. Therefore, although 150-300 minutes/week of moderate intensity, or 75-150 minutes/week of vigorous intensity aerobic exercise is preferred, it is recommended that even those who cannot achieve these levels be encouraged to stay as active as their abilities and health conditions allow, while reducing sedentary time to reduce CV risk.⁸

The guidelines also recommend exercise-based cardiac rehabilitation programs for patients for secondary prevention and for patients with HF.⁸ Programs should be medically supervised, multidisciplinary, and comprehensive, and home-based interventions can be considered. Exercise-based cardiac rehabilitation should include both aerobic and muscular resistance exercise, address all recognized CV risk factors, and should be individualised.

4 **Treatment decisions: When should we use aggressive interventions vs. 5 medication vs. no treatment?** 6 7 8 9

10 **Decision making for antithrombotic treatments in older people (antiplatelet, anticoagulant, 11 and combination therapy)** 12 13 14

15
16 Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in adults, and
17 the prevalence is expected to double by 2060.⁷⁴ Increasing age is an important risk factor, and
18 approximately 70% of patients are 65-85 years old.⁷⁵ However, these patients are also at
19 increased risk of bleeding, which makes the use of antithrombotic therapies one of the most
20 challenging management decisions in older people.^{76, 77}
21
22

23
24 Non-vitamin K antagonist oral anticoagulants (NOACs) have demonstrated improved
25 efficacy and safety compared to warfarin in older people.⁷⁸ A meta-analysis of RCTs included
26 71,683 older people with AF, of whom 30-40% of were ≥ 75 years.⁷⁸ NOACs significantly
27 reduced stroke or systemic embolic events by 19% (relative risk 0.81, 95% CI 0.73-0.91;
28 $p < 0.0001$) compared with warfarin. Although there was a greater risk of gastrointestinal
29 bleeding, NOACs significantly reduced all-cause mortality and intracranial haemorrhage, with a
30 similar risk of major bleeding compared to warfarin. Results were consistent in patients < 75 and
31 ≥ 75 years.⁷⁸ Low-dose NOAC regimens yielded similar benefits, with a better safety profile than
32 warfarin, and thus, might be useful for patients who have a high bleeding risk.⁷⁸
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

50 Bleeding risk is also a major concern in older patients with AF and concomitant coronary
51 artery disease (CAD) who need both anticoagulant (e.g., NOAC or vitamin K antagonist [VKA])
52 and antiplatelet therapy (e.g., aspirin or a P2Y12 inhibitor).^{79, 80} Dual therapy has been associated
53 with increased bleeding, and increased mortality,^{80, 81} and triple therapy (e.g., NOAC, aspirin,
54
55
56
57
58
59
60
61
62
63
64
65

4 and clopidogrel), has been associated with higher risks compared to dual therapy or
5
6 monotherapy.^{81, 82}
7
8

9 The 2021 European guidelines recommend restricting the use of concomitant
10 anticoagulant and antiplatelet therapy to patients with a clear indication for both (e.g., AF plus
11 PAD, CAD or cerebrovascular disease, particularly if treated with percutaneous revascularization
12 and stent implantation). Further, a NOAC is preferred over a VKA, dual therapy should be
13
14 continued for only 6-12 months, and duration of use of triple therapy including aspirin should be
15
16 minimized.^{74, 83}
17
18
19
20
21
22

23 However, the guidelines state that an elevated risk of bleeding is not a reason to withhold
24 anticoagulants or to automatically use lower doses, even for older patients.⁷⁴ Rather, therapy
25
26 should be individualised, modifiable risk factors addressed, and patients should be followed-up
27
28 more frequently. Similarly, frailty, risk of falls, and cognitive issues are not reasons to withhold
29
30 therapy.⁷⁴ Shared-decision making, with benefit/risk discussions can help in determining the best
31
32 strategy for an individual.
33
34
35
36
37
38

39 **Decision-making for invasive procedures in older people** 40

41
42 Historically there has been a reluctance to perform complex percutaneous coronary
43 intervention (PCI) in older patients. Older people may have more extensive or more severe CAD
44 and be at higher CV risk, and may have a higher risk of post-procedure complications.⁸⁴
45
46 However, improvements in equipment and techniques have led to high success rates and low
47 complications rates among older patients.⁸⁴ Treatment with revascularization and medical
48
49 devices, such as transcatheter aortic-valve implantation (TAVI) and transcatheter mitral-valve
50
51 repair (TMVR) can be highly effective in reducing the risk of MACE.^{85, 86} In addition, TAVI and
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2
3
4 TMVR have not been associated with the risk of major bleeding, even in older patients,
5
6 compared to that seen with surgical treatment.^{85, 86}
7
8

9 Similarly, even among patients ≥ 75 years, observational studies and RCTs have shown
10
11 lower rates of MACE and mortality with revascularization (coronary artery bypass graft [CABG]
12
13 or PCI) compared with medical treatment.^{87, 88} In addition, patients experienced improvements in
14
15 angina severity and quality of life.⁸⁸
16
17

18 19 *When, who, and how to perform revascularization*

20
21
22 Myocardial revascularization should be performed to improve prognosis or symptoms as
23
24 recommended in the 2018 European guidelines on myocardial revascularization (Table 2).⁸⁹
25
26 Shared-decision-making should include consultation with a heart team, thoroughly informing the
27
28 patient of the benefits and risks, and consideration of patient preferences.
29
30
31

32 CABG has been associated with lower rates of mortality compared to PCI in RCTs in
33
34 patients with left main disease or triple vessel disease.⁹⁰ However, frail patients, especially those
35
36 with left main disease were excluded from these trials.^{84, 91} The guidelines on myocardial
37
38 revascularization recommend using the SYNTAX score to help guide decisions on whether to
39
40 perform PCI or CABG.^{89, 92} PCI is generally recommended in patients with low SYNTAX
41
42 scores, mainly because of convenience and cost. CABG is recommended in patients with
43
44 intermediate or high SYNTAX scores because of with the potential for lower mortality rates.⁹²
45
46 However, the choice should also consider the presence of severe co-morbidities, advanced age
47
48 (e.g., frailty or reduced life expectancy), and conditions that may affect rehabilitation (e.g.,
49
50 restricted mobility) favour PCI.^{89, 92}
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4 *When, who, and how to perform aortic or percutaneous mitral valve interventions*
5
6

7 Updated European guidelines on valvular heart disease were published in 2021, and a
8 summary of recommendations for the use of interventions in patients with aortic stenosis and
9 mitral regurgitation is shown in **Table 3**.⁹³ In addition, the Aortic Valve ReplAcemenT versus
10 Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis (AVATAR) study suggested
11 that surgical aortic valve replacement (SAVR) is beneficial when stenosis becomes severe
12 regardless of symptoms.⁹⁴
13
14

15 TAVI has been associated with reduced rates of all-cause mortality and stroke compared
16 with SAVR, regardless of baseline surgical risk.⁹⁵ Stroke may be an important outcome for older
17 people because of the impact on quality of life.
18
19

20 Certain clinical, anatomical, and technical factors should be considered in the decision to
21 perform SAVR or TAVI, and risks and benefits should be discussed with a heart team and an
22 informed patient.^{93, 96, 97} SAVR is favoured in patients with complex anatomy, concomitant
23 conditions that require surgery such as significant CAD, or those with endocarditis. Life
24 expectancy, potential quality of life in terms of comorbid conditions or frailty, together with
25 well-informed patient preferences are critical in determining the best management strategy.
26 Delirium can be an important complication after TAVI, especially in older people, who may
27 benefit from early recognition and interventions.⁹⁸
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Adding years to life or life to years (making decisions to withhold or discontinue treatment)

The main goals of CV treatments should be to prevent or manage CVD, and to improve the quality and duration of life (healthy active life).¹⁵ Patient preference becomes a primary factor in chronic, incurable, or highly disabling conditions such as advanced HF.^{15, 99} Individuals have different beliefs, values, and goals regarding their health care, and these may change over time.¹⁵

Improved treatments and longer survival in patients with HF is associated with more hospitalizations and an increasingly unmanageable symptom burden.⁹⁹ CV risk factors alone should not determine therapy, rather risk minimization strategies should be preferred. Patients may benefit from proactive strategies to address side effects, or from discontinuation of some medications. Studies suggest that reducing the number of drugs in older patients on polypharmacy (including CV and/or non-CV medications) can be done safely, and has the potential to reduce falls, improve quality of life, reduce medication burden, and reduce medication costs.^{15, 28-30}

In patients with cancer, palliative care has significantly improved quality of life and survival.¹⁰⁰ In cardiology, palliative care becomes especially important in patients with HF. HF is a progressive, chronic, life-threatening condition that significantly impacts quality of life. In addition, HF is often the end stage of most chronic CV conditions. In a RCT in patients with advanced HF, an interdisciplinary palliative care intervention was associated with significant improvements in quality of life measures, and depression and anxiety scores compared with usual care alone.¹⁰¹ This illustrates that the risk is actionable and can be influenced.

4 ESC HF guidelines suggest healthcare providers focus on the quality of life and the
5 symptom burden of patients with advanced heart failure, as well as a timely plan for palliative
6 care based on the patient's needs and beliefs (Table 4).¹⁰² Patients with HF can benefit from
7 palliative care not only to help manage their symptoms, but also to achieve a better
8 understanding of their disease. With the patient's permission collateral information should be
9 obtained from the family (e.g., in patients with cognitive impairment), and relatives should be
10 included in discussions.
11
12
13
14
15
16
17
18
19
20

21 Despite favourable scientific evidence, palliative care has not been well integrated into
22 cardiology.⁹⁹ Communication requires time, therefore, pathways should be in place for referral to
23 palliative care, incorporating a shared-care strategy.¹⁰² Palliative care should be discussed early
24 in the disease trajectory, and end-of-life discussions should include advance care planning,
25 disease understanding, and the patients' goals of care, with the goal of helping patients
26 understand their disease status, prognosis, treatment options, and facilitate decision-making.^{99, 102}
27
28 In patients with HF who are very debilitated and frail, palliative care can provide psychosocial
29 support in making complex decisions such as device deactivation and place of death
30 preferences.^{99, 102} A close collaboration between the palliative care team and the cardiologists is
31 definitively needed, especially with mobile palliative care teams, and should improve the
32 management of elderly patients requiring palliative care. Understanding and expanding the role
33 of palliative care in cardiology is a much needed area for further investigation.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54 **Summary**

55
56

57 The growing elderly population worldwide represents a major responsibility, but also a
58 challenge for caregivers, healthcare providers, and society. The life-long exposure to CV risk
59
60
61
62
63
64
65

4 factors, as well as age-related comorbidities, promote a high prevalence of frequently
5
6 complicated CVD in older patients. While prevention and management strategies have been
7
8 shown to be effective in older people, there continues to be a paucity of robust evidence from
9
10 dedicated clinical trials. The narrow therapeutic window of some recommended
11
12 pharmacotherapies, frailty and cognitive impairments, and patients' re-assessment of important
13
14 outcomes (e.g., quality of life versus mortality), can present management challenges.
15
16
17
18

19 With the increasing burden of ageing, the time has come to revisit CV research, including
20
21 increasing use of real-world studies to assess longer-term outcomes. Use of pharmacological and
22
23 interventional strategies in older patients should focus on quality of life and patient's
24
25 preferences, with the optimal strategy being determined by a multidisciplinary team who
26
27 involves the individual patient into the decision-making process.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4 **Acknowledgements**

7
8 This article was generated from discussions during a virtual Cardiovascular Round Table
9
10 (CRT) workshop organised in May 2021 by the European Society of Cardiology (ESC). The
11
12 ESC CRT is a strategic forum for high-level dialogue between 20 industry companies
13
14 (pharmaceutical, devices and diagnostics) and the ESC leadership to identify and discuss key
15
16 strategic issues for the future of cardiovascular health in Europe. The authors would like to thank
17
18 Pauline Lavigne and Steven Portelance (unaffiliated, supported by the ESC) for contributions to
19
20 writing, and editing the manuscript.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4 **Disclosures**

5
6
7 Lettino: Honoraria from Bristol-Meyers Squibb, Pfizer, Sanofi, Boehringer Ingelheim, Daiichi
8
9 Sankyo, and Edwards Lifescience; advisory board participation for Boehringer Ingelheim and
10
11 Edwards Lifescience; and a leadership role (President) with a multi-hospital Institutional Review
12
13 Board.
14

15
16 Mascherbauer: None.
17

18
19 Nordaby: Employment with Boehringer Ingelheim International.
20

21
22 Ziegler: None.
23

24 Collet: Grants or contracts from Bristol-Myers Squibb, Medtronic, and Pfizer; and honoraria
25
26 from Abbott, AstraZeneca, Boston Scientific, and Sanofi.
27

28 Derumeaux: Institutional grants to INSERM (RHU CARMMA) from Agence Nationale pour la
29
30 Recherche (ANR).
31

32
33 Hohnloser: Consulting fees from Bristol-Meyers Squibb, Pfizer, Boehringer Ingelheim, Bayer,
34
35 and Daiichi Sankyo; and honoraria from Bristol-Meyers Squibb, Pfizer, Boehringer Ingelheim,
36
37 Bayer, and Daiichi Sankyo.
38

39
40 Leclercq: None.
41

42
43 O'Neill: Honoraria from Servier Canada.
44

45
46 Visseren: Research funding from Amgen.
47

48
49 Weidinger: None.
50

51 Richard-Lordereau: Employment with and stock options from Amgen.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

4 **Author contributions**

5
6
7 All CRT members that were included as authors contributed to design of the CRT meeting and to
8
9 selection of the topics; ML and IR-L drafted the initial manuscript. All authors critically revised
10
11 the manuscript, gave final approval, and agreed to be accountable for all aspects of work
12
13
14 ensuring integrity and accuracy.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Graphical abstract





Figure legend

Figure 1: Individualised decisions on lifestyle changes and risk factor treatment will benefit from a thorough risk analysis and patient involvement



References

1. Eurostat. *Population on 1st January by age, sex and type of projection (code: proj_19NP)*. https://ec.europa.eu/eurostat/en/web/products-datasets/-/proj_19NP (June 3 2021).
2. Eurostat. *Population on 1 January by age group and sex (code: demo_pjangroup)*. https://ec.europa.eu/eurostat/en/web/products-datasets/-/DEMO_PJANGROUP (June 3 2021).
3. Rodgers JL, Jones J, Bolleddu SI, Vanthenapalli S, Rodgers LE, Shah K, Karia K, Panguluri SK. Cardiovascular risks associated with gender and aging. *J Cardiovasc Dev Dis* 2019;**6**(2).
4. Skirbekk VF, Staudinger UM, Cohen JE. How to measure population aging? The answer is less than obvious: A review. *Gerontology* 2019;**65**(2):136-144.
5. Zaidi A, Gasior K, Zolyomi E, Schmidt A, Rodrigues R, Marin B. Measuring active and healthy ageing in Europe. *J Eur Social Policy* 2017;**27**(2):138-157.
6. Singh S, Bajorek B. Defining 'elderly' in clinical practice guidelines for pharmacotherapy. *Pharm Pract (Granada)* 2014;**12**(4):489.
7. Score2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. *Eur Heart J* 2021;**42**(25):2455-2467.
8. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C, Williams B, ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;**42**(34):3227-3337.
9. Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, Geisel MH, Lehmann N, Erbel R, Jockel KH, van der Graaf Y, Verschuren WMM, Boer JMA, Nambi V, Visseren FLJ, Dorresteijn JAN. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. *Eur Heart J* 2020;**41**(11):1190-1199.
10. Stam-Slob MC, Visseren FL, Wouter Jukema J, van der Graaf Y, Poulter NR, Gupta A, Sattar N, Macfarlane PW, Kearney PM, de Craen AJ, Trompet S. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. *Clin Res Cardiol* 2017;**106**(1):58-68.
11. Cooney MT, Selmer R, Lindman A, Tverdal A, Menotti A, Thomsen T, DeBacker G, De Bacquer D, Tell GS, Njolstad I, Graham IM, Score, investigators C. Cardiovascular risk estimation in older persons: SCORE O.P. *Eur J Prev Cardiol* 2016;**23**(10):1093-103.
12. Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, Bonnefoy-Cudraz E, Cobain M, Piepoli MF, Visseren FL, Dendale P, This Paper Is AC-PBEJOPCEHJACC, European Journal Of Cardiovascular N. Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the

- Association of Cardiovascular Nursing and Allied Professions (ACNAP). *Eur J Prev Cardiol* 2019;**26**(14):1534-1544.
13. Gooding HC, Gidding SS, Moran AE, Redmond N, Allen NB, Bacha F, Burns TL, Catov JM, Grandner MA, Harris KM, Johnson HM, Kiernan M, Lewis TT, Matthews KA, Monaghan M, Robinson JG, Tate D, Bibbins-Domingo K, Spring B. Challenges and opportunities for the prevention and treatment of cardiovascular disease among young adults: Report from a National Heart, Lung, and Blood Institute Working Group. *J Am Heart Assoc* 2020;**9**(19):e016115.
 14. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Munoz D, Smith SC, Jr., Virani SS, Williams KA, Sr., Yeboah J, Ziaeian B. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation* 2019;**140**(11):e596-e646.
 15. Krishnaswami A, Steinman MA, Goyal P, Zullo AR, Anderson TS, Birtcher KK, Goodlin SJ, Maurer MS, Alexander KP, Rich MW, Tjia J, Geriatric Cardiology Section Leadership Council American College of Cardiology. Deprescribing in older adults with cardiovascular disease. *J Am Coll Cardiol* 2019;**73**(20):2584-2595.
 16. Rovio SP, Pahkala K, Raitakari OT. Cognitive decline before and after incident coronary heart disease: Opportunity to intervene cognitive function trajectories. *J Am Coll Cardiol* 2019;**73**(24):3051-3053.
 17. Wijsman LW, de Craen AJ, Trompet S, Sabayan B, Muller M, Stott DJ, Ford I, Welsh P, Westendorp RG, Jukema JW, Sattar N, Mooijaart SP. High-sensitivity cardiac troponin T is associated with cognitive decline in older adults at high cardiovascular risk. *Eur J Prev Cardiol* 2016;**23**(13):1383-92.
 18. Xie W, Zheng F, Yan L, Zhong B. Cognitive decline before and after incident coronary events. *J Am Coll Cardiol* 2019;**73**(24):3041-3050.
 19. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Cheng S, Delling FN, Elkind MSV, Evenson KR, Ferguson JF, Gupta DK, Khan SS, Kissela BM, Knutson KL, Lee CD, Lewis TT, Liu J, Loop MS, Lutsey PL, Ma J, Mackey J, Martin SS, Matchar DB, Mussolino ME, Navaneethan SD, Perak AM, Roth GA, Samad Z, Satou GM, Schroeder EB, Shah SH, Shay CM, Stokes A, VanWagner LB, Wang NY, Tsao CW, American Heart Association Council on Epidemiology, Prevention Statistics Committee, Subcommittee. SS. Heart disease and stroke statistics-2021 update: A report from the American Heart Association. *Circulation* 2021;**143**(8):e254-e743.
 20. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991;**265**(24):3255-64.
 21. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. *Lancet* 1997;**350**(9080):757-64.

- 1
2
3
4 22. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V,
5 Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L,
6 Banya W, Bulpitt CJ, Group HS. Treatment of hypertension in patients 80 years of age or
7 older. *N Engl J Med* 2008;**358**(18):1887-98.
- 8
9 23. Sprint Research Group, Wright JT, Jr., Williamson JD, Whelton PK, Snyder JK, Sink
10 KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson
11 KC, Goff DC, Jr., Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A
12 randomized trial of intensive versus standard blood-pressure control. *N Engl J Med*
13 2015;**373**(22):2103-16.
- 14
15 24. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, Bulpitt C,
16 Peters R. No evidence that frailty modifies the positive impact of antihypertensive
17 treatment in very elderly people: an investigation of the impact of frailty upon treatment
18 effect in the Hypertension in the Very Elderly Trial (HYVET) study, a double-blind,
19 placebo-controlled study of antihypertensives in people with hypertension aged 80 and
20 over. *BMC Med* 2015;**13**:78.
- 21
22 25. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow
23 GM, Fine LJ, Haley WE, Hawfield AT, Ix JH, Kitzman DW, Kostis JB, Krousel-Wood
24 MA, Launer LJ, Oparil S, Rodriguez CJ, Roumie CL, Shorr RI, Sink KM, Wadley VG,
25 Whelton PK, Whittle J, Woolard NF, Wright JT, Jr., Pajewski NM, Group SR. Intensive
26 vs standard blood pressure control and cardiovascular disease outcomes in adults aged
27 ≥ 75 years: A randomized clinical trial. *JAMA* 2016;**315**(24):2673-82.
- 28
29 26. Bress AP, Kramer H, Khatib R, Beddhu S, Cheung AK, Hess R, Bansal VK, Cao G, Yee
30 J, Moran AE, Durazo-Arvizu R, Muntner P, Cooper RS. Potential deaths averted and
31 serious adverse events incurred from adoption of the SPRINT (Systolic Blood Pressure
32 Intervention Trial) intensive blood pressure regimen in the United States: Projections
33 from NHANES (National Health and Nutrition Examination Survey). *Circulation*
34 2017;**135**(17):1617-1628.
- 35
36 27. Benetos A, Petrovic M, Strandberg T. Hypertension management in older and frail older
37 patients. *Circ Res* 2019;**124**(7):1045-1060.
- 38
39 28. Kutner JS, Blatchford PJ, Taylor DH, Jr., Ritchie CS, Bull JH, Fairclough DL, Hanson
40 LC, LeBlanc TW, Samsa GP, Wolf S, Aziz NM, Currow DC, Ferrell B, Wagner-
41 Johnston N, Zafar SY, Cleary JF, Dev S, Goode PS, Kamal AH, Kassner C, Kvale EA,
42 McCallum JG, Ogunseitan AB, Pantilat SZ, Portenoy RK, Prince-Paul M, Sloan JA,
43 Swetz KM, Von Gunten CF, Abernethy AP. Safety and benefit of discontinuing statin
44 therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. *JAMA*
45 *Intern Med* 2015;**175**(5):691-700.
- 46
47 29. Kua CH, Mak VSL, Huey Lee SW. Health outcomes of deprescribing interventions
48 among older residents in nursing homes: A systematic review and meta-analysis. *J Am*
49 *Med Dir Assoc* 2019;**20**(3):362-372 e11.
- 50
51 30. Ibrahim K, Cox NJ, Stevenson JM, Lim S, Fraser SDS, Roberts HC. A systematic review
52 of the evidence for deprescribing interventions among older people living with frailty.
53 *BMC Geriatr* 2021;**21**(1):258.
- 54
55 31. Williams B, Mancina G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL,
56 Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L,
57 Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R,
58 Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V,
59
60
61
62
63
64
65

- Desormais I, ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J* 2018;**39**(33):3021-3104.
32. Rosada A, Kassner U, Weidemann F, König M, Buchmann N, Steinhagen-Thiessen E, Spira D. Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. *Lipids Health Dis* 2020;**19**(1):92.
33. Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019;**393**(10170):407-415.
34. Gencer B, Marston NA, Im K, Cannon CP, Sever P, Keech A, Braunwald E, Giugliano RP, Sabatine MS. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials. *Lancet* 2020;**396**(10263):1637-1643.
35. Savarese G, Gotto AM, Jr., Paolillo S, D'Amore C, Losco T, Musella F, Scala O, Marciano C, Ruggiero D, Marsico F, De Luca G, Trimarco B, Perrone-Filardi P. Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. *J Am Coll Cardiol* 2013;**62**(22):2090-9.
36. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C, Westendorp RG, Risk PsgPSoPitEa. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002;**360**(9346):1623-30.
37. Yourman LC, Cenzer IS, Boscardin WJ, Nguyen BT, Smith AK, Schonberg MA, Schoenborn NL, Widera EW, Orkaby A, Rodriguez A, Lee SJ. Evaluation of time to benefit of statins for the primary prevention of cardiovascular events in adults aged 50 to 75 years: A meta-analysis. *JAMA Intern Med* 2021;**181**(2):179-185.
38. Holmes HM, Min LC, Yee M, Varadhan R, Basran J, Dale W, Boyd CM. Rationalizing prescribing for older patients with multimorbidity: considering time to benefit. *Drugs Aging* 2013;**30**(9):655-66.
39. *A clinical trial of statin therapy for reducing events in the elderly (STAREE)*. <https://clinicaltrials.gov/ct2/show/NCT02099123> (June 30 2021).
40. *Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults (PREVENTABLE)*. <https://clinicaltrials.gov/ct2/show/NCT04262206> (June 30 2021).
41. Fazeli PK, Lee H, Steihauser ML. Aging is a powerful risk factor for type 2 diabetes mellitus independent of body mass index. *Gerontology* 2020;**66**(2):209-210.
42. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). *Lancet* 1998;**352**(9131):854-65.
43. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, Federici M, Filippatos G, Grobbee DE, Hansen TB, Huikuri HV, Johansson I, Juni P, Lettino M, Marx N, Mellbin LG, Ostgren CJ, Rocca B, Roffi M, Sattar N, Seferovic PM, Sousa-Uva M, Valensi P, Wheeler DC, ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J* 2020;**41**(2):255-323.
44. Monteiro P, Bergenstal RM, Toural E, Inzucchi SE, Zinman B, Hantel S, Kis SG, Kaspers S, George JT, Fitchett D. Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME(R) trial. *Age Ageing* 2019;**48**(6):859-866.

- 1
2
3
4 45. Cahn A, Mosenzon O, Wiviott SD, Rozenberg A, Yanuv I, Goodrich EL, Murphy SA,
5 Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Gause-Nilsson IAM, Fredriksson M,
6 Johansson PA, Langkilde AM, Sabatine MS, Raz I. Efficacy and safety of dapagliflozin
7 in the elderly: Analysis from the DECLARE-TIMI 58 study. *Diabetes Care*
8 2020;**43**(2):468-475.
- 9
10 46. Leiter LA, Bain SC, Hramiak I, Jodar E, Madsbad S, Gondolf T, Hansen T, Holst I,
11 Lingvay I. Cardiovascular risk reduction with once-weekly semaglutide in subjects with
12 type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the
13 SUSTAIN 6 trial. *Cardiovasc Diabetol* 2019;**18**(1):73.
- 14
15 47. Riddle MC, Gerstein HC, Xavier D, Cushman WC, Leiter LA, Raubenheimer PJ, Atisso
16 CM, Raha S, Varnado OJ, Konig M, Lakshmanan M, Franek E. Efficacy and safety of
17 dulaglutide in older patients: A post hoc analysis of the REWIND trial. *J Clin Endocrinol*
18 *Metab* 2021;**106**(5):1345-1351.
- 19
20 48. Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, Rea RR, Kerr
21 Saraiva JF, Rasmussen S, Tornoe K, von Scholten BJ, Buse JB, Investigators
22 LPCobotLT. Effect of liraglutide on cardiovascular outcomes in elderly patients: A post
23 hoc analysis of a randomized controlled trial [Letter]. *Ann Intern Med* 2019;**170**(6):423-
24 426.
- 25
26 49. Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G,
27 Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G, ARRIVE Executive
28 Committee. Use of aspirin to reduce risk of initial vascular events in patients at moderate
29 risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled
30 trial. *Lancet* 2018;**392**(10152):1036-1046.
- 31
32 50. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens
33 W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay
34 M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil
35 A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J. Effects of aspirin for
36 primary prevention in persons with diabetes mellitus. *N Engl J Med* 2018;**379**(16):1529-
37 1539.
- 38
39 51. McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah
40 RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL,
41 Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin
42 LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R, Murray AM, Group
43 AI. Effect of aspirin on all-cause mortality in the healthy elderly. *N Engl J Med*
44 2018;**379**(16):1519-1528.
- 45
46 52. McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM,
47 Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME,
48 Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ,
49 Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton CB, Brauer D, Cloud
50 G, Wood EM, Mahady SE, Satterfield S, Grimm R, Murray AM, Group AI. Effect of
51 aspirin on cardiovascular events and bleeding in the healthy elderly. *N Engl J Med*
52 2018;**379**(16):1509-1518.
- 53
54 53. Abdelaziz HK, Saad M, Pothineni NVK, Megaly M, Potluri R, Saleh M, Kon DLC,
55 Roberts DH, Bhatt DL, Aronow HD, Abbott JD, Mehta JL. Aspirin for primary
56 prevention of cardiovascular events. *J Am Coll Cardiol* 2019;**73**(23):2915-2929.
- 57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
54. By the American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria(R) for potentially inappropriate medication use in older adults. *J Am Geriatr Soc* 2019;**67**(4):674-694.
55. Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, Butalia S, Leung AA, Harris KC, Cloutier L, Zarnke KB, Ruzicka M, Hiremath S, Feldman RD, Tobe SW, Campbell TS, Bacon SL, Nerenberg KA, Dresser GK, Fournier A, Burgess E, Lindsay P, Rabkin SW, Prebtani APH, Grover S, Honos G, Alfonsi JE, Arcand J, Audibert F, Benoit G, Bittman J, Bolli P, Cote AM, Dionne J, Don-Wauchope A, Edwards C, Firoz T, Gabor JY, Gilbert RE, Gregoire JC, Gryn SE, Gupta M, Hannah-Shmouni F, Hegele RA, Herman RJ, Hill MD, Howlett JG, Hundemer GL, Jones C, Kaczorowski J, Khan NA, Kuyper LM, Lamarre-Cliche M, Lavoie KL, Leiter LA, Lewanczuk R, Logan AG, Magee LA, Mangat BK, McFarlane PA, McLean D, Michaud A, Milot A, Moe GW, Penner SB, Pipe A, Poppe AY, Rey E, Roerecke M, Schiffrin EL, Selby P, Sharma M, Shoamanesh A, Sivapalan P, Townsend RR, Tran K, Trudeau L, Tsuyuki RT, Vallee M, Woo V, Bell AD, Daskalopoulou SS. Hypertension Canada's 2020 comprehensive guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. *Can J Cardiol* 2020;**36**(5):596-624.
56. Hawk ET, Maresso KC. The ASPREE trial: An unanticipated stimulus for greater precision in prevention? *J Natl Cancer Inst* 2021;**113**(3):221-222.
57. Lewis J, Bethishou L, Tsu LV. Aspirin use for primary prevention of cardiovascular disease in older patients: A review of clinical guidelines and updated evidence. *Sr Care Pharm* 2019;**34**(9):580-594.
58. Ezzati M, Henley SJ, Thun MJ, Lopez AD. Role of smoking in global and regional cardiovascular mortality. *Circulation* 2005;**112**(4):489-97.
59. Mons U, Muezzinler A, Gellert C, Schottker B, Abnet CC, Bobak M, de Groot L, Freedman ND, Jansen E, Kee F, Kromhout D, Kuulasmaa K, Laatikainen T, O'Doherty MG, Bueno-de-Mesquita B, Orfanos P, Peters A, van der Schouw YT, Wilsgaard T, Wolk A, Trichopoulou A, Boffetta P, Brenner H, Consortium C. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. *BMJ* 2015;**350**:h1551.
60. Ahmed AA, Patel K, Nyaku MA, Kheirbek RE, Bittner V, Fonarow GC, Filippatos GS, Morgan CJ, Aban IB, Mujib M, Desai RV, Allman RM, White M, Deedwania P, Howard G, Bonow RO, Fletcher RD, Aronow WS, Ahmed A. Risk of heart failure and death after prolonged smoking cessation: Role of amount and duration of prior smoking. *Circ Heart Fail* 2015;**8**(4):694-701.
61. Estruch R, Ros E, Salas-Salvado J, Covas MI, Corella D, Aros F, Gomez-Gracia E, Ruiz-Gutierrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pinto X, Basora J, Munoz MA, Sorli JV, Martinez JA, Martinez-Gonzalez MA, Investigators PS. Primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2013;**368**(14):1279-90.
62. Trichopoulou A, Orfanos P, Norat T, Bueno-de-Mesquita B, Ocke MC, Peeters PH, van der Schouw YT, Boeing H, Hoffmann K, Boffetta P, Nagel G, Masala G, Krogh V, Panico S, Tumino R, Vineis P, Bamia C, Naska A, Benetou V, Ferrari P, Slimani N, Pera G, Martinez-Garcia C, Navarro C, Rodriguez-Barranco M, Dorronsoro M, Spencer EA, Key TJ, Bingham S, Khaw KT, Kesse E, Clavel-Chapelon F, Boutron-Ruault MC,

- Berglund G, Wirfalt E, Hallmans G, Johansson I, Tjonneland A, Olsen A, Overvad K, Hundborg HH, Riboli E, Trichopoulos D. Modified Mediterranean diet and survival: EPIC-elderly prospective cohort study. *BMJ* 2005;**330**(7498):991.
63. Al-Khudairy L, Flowers N, Wheelhouse R, Ghannam O, Hartley L, Stranges S, Rees K. Vitamin C supplementation for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2017;**3**:CD011114.
64. Barbarawi M, Kheiri B, Zayed Y, Barbarawi O, Dhillon H, Swaid B, Yelangi A, Sundus S, Bachuwa G, Alkotob ML, Manson JE. Vitamin D supplementation and cardiovascular disease risks in more than 83000 individuals in 21 randomized clinical trials: A meta-analysis. *JAMA Cardiol* 2019;**4**(8):765-776.
65. Sesso HD, Buring JE, Christen WG, Kurth T, Belanger C, MacFadyen J, Bubes V, Manson JE, Glynn RJ, Gaziano JM. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized controlled trial. *JAMA* 2008;**300**(18):2123-33.
66. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, Gibson H, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, Vital Research Group. Vitamin D supplements and prevention of cancer and cardiovascular disease. *N Engl J Med* 2019;**380**(1):33-44.
67. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, Summerbell CD, Worthington HV, Song F, Hooper L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2020;**3**:CD003177.
68. Khan SU, Lone AN, Khan MS, Virani SS, Blumenthal RS, Nasir K, Miller M, Michos ED, Ballantyne CM, Boden WE, Bhatt DL. Effect of omega-3 fatty acids on cardiovascular outcomes: A systematic review and meta-analysis. *EClinicalMedicine* 2021;**38**:100997.
69. Hakim AA, Curb JD, Petrovitch H, Rodriguez BL, Yano K, Ross GW, White LR, Abbott RD. Effects of walking on coronary heart disease in elderly men: The Honolulu Heart Program. *Circulation* 1999;**100**(1):9-13.
70. Bijnen FC, Caspersen CJ, Feskens EJ, Saris WH, Mosterd WL, Kromhout D. Physical activity and 10-year mortality from cardiovascular diseases and all causes: The Zutphen Elderly Study. *Arch Intern Med* 1998;**158**(14):1499-505.
71. Kim K, Choi S, Hwang SE, Son JS, Lee JK, Oh J, Park SM. Changes in exercise frequency and cardiovascular outcomes in older adults. *Eur Heart J* 2020;**41**(15):1490-1499.
72. Lachman S, Boekholdt SM, Luben RN, Sharp SJ, Brage S, Khaw KT, Peters RJ, Wareham NJ. Impact of physical activity on the risk of cardiovascular disease in middle-aged and older adults: EPIC Norfolk prospective population study. *Eur J Prev Cardiol* 2018;**25**(2):200-208.
73. Cheng S-J, Yu H-K, Chen Y-C, Chen C-Y, Lien W-C, Yang P-W, Hu G-C. Physical activity and risk of cardiovascular disease among older adults. *Int J Gerontology* 2013;**7**:133-6.
74. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, Fauchier L, Filippatos G, Kalman JM, La Meir M, Lane DA, Lebeau JP, Lettino M, Lip GYH, Pinto FJ, Thomas GN, Valgimigli M, Van Gelder IC, Van Putte BP, Watkins CL, ESC Scientific Document Group. 2020 ESC

- Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021;**42**(5):373-498.
75. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. *Arch Intern Med* 1995;**155**(5):469-73.
76. Karamichalakis N, Georgopoulos S, Vlachos K, Liatakis I, Efremidis M, Sideris A, Letsas KP. Efficacy and safety of novel anticoagulants in the elderly. *J Geriatr Cardiol* 2016;**13**(8):718-723.
77. Schafer A, Flierl U, Berliner D, Bauersachs J. Anticoagulants for stroke prevention in atrial fibrillation in elderly patients. *Cardiovasc Drugs Ther* 2020;**34**(4):555-568.
78. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;**383**(9921):955-62.
79. Martin R, Bates M. Management of atrial fibrillation and concomitant coronary artery disease. *Continuing Cardiology Education* 2017;**3**(2):47-55.
80. Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, Miyauchi K, Hagiwara N, Kimura K, Hirayama A, Matsui K, Ogawa H, Investigators A. Antithrombotic therapy for atrial fibrillation with stable coronary disease. *N Engl J Med* 2019;**381**(12):1103-1113.
81. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. *Circulation* 2011;**123**(21):2363-72.
82. Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, Goodman SG, Windecker S, Darius H, Li J, Averkov O, Bahit MC, Berwanger O, Budaj A, Hijazi Z, Parkhomenko A, Sinnaeve P, Storey RF, Thiele H, Vinereanu D, Granger CB, Alexander JH, Investigators A. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. *N Engl J Med* 2019;**380**(16):1509-1524.
83. Lettino M, Leonardi S, De Maria E, Halvorsen S. Antiplatelet and antithrombotic treatment for secondary prevention in ischaemic heart disease. *Eur J Prev Cardiol* 2017;**24**(3_suppl):61-70.
84. Guo L, Lv HC, Huang RC. Percutaneous coronary intervention in elderly patients with coronary chronic total occlusions: Current evidence and future perspectives. *Clin Interv Aging* 2020;**15**:771-781.
85. Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, Investigators C. Transcatheter mitral-valve repair in patients with heart failure. *N Engl J Med* 2018;**379**(24):2307-2318.
86. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S,

- Investigators PT. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;**363**(17):1597-607.
87. Flores-Umanzor EJ, Vazquez S, Cepas-Guillen P, Ivey-Miranda J, Caldentey G, Jimenez-Britez G, Regueiro A, Freixa X, Andrea R, Ferreira-Gonzalez I, Sabate M, Martin-Yuste V. Impact of revascularization versus medical therapy alone for chronic total occlusion management in older patients. *Catheter Cardiovasc Interv* 2019;**94**(4):527-535.
88. Time Investigators. Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. *Lancet* 2001;**358**(9286):951-7.
89. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Juni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferovic PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO, ESC Scientific Document Group. 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J* 2019;**40**(2):87-165.
90. Hlatky MA, Boothroyd DB, Bravata DM, Boersma E, Booth J, Brooks MM, Carrie D, Clayton TC, Danchin N, Flather M, Hamm CW, Hueb WA, Kahler J, Kelsey SF, King SB, Kosinski AS, Lopes N, McDonald KM, Rodriguez A, Serruys P, Sigwart U, Stables RH, Owens DK, Pocock SJ. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. *Lancet* 2009;**373**(9670):1190-7.
91. Sabatine MS, Bergmark BA, Murphy SA, O'Gara PT, Smith PK, Serruys PW, Kappetein AP, Park SJ, Park DW, Christiansen EH, Holm NR, Nielsen PH, Stone GW, Sabik JF, Braunwald E. Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. *Lancet* 2021;**398**(10318):2247-2257.
92. Windecker S, Neumann FJ, Juni P, Sousa-Uva M, Falk V. Considerations for the choice between coronary artery bypass grafting and percutaneous coronary intervention as revascularization strategies in major categories of patients with stable multivessel coronary artery disease: an accompanying article of the task force of the 2018 ESC/EACTS guidelines on myocardial revascularization. *Eur Heart J* 2019;**40**(2):204-212.
93. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, Juni P, Pierard L, Prendergast BD, Sadaba JR, Tribouilloy C, Wojakowski W, Group EESD, Group ESCSD. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J* 2021.
94. Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, Kotrc M, Glaveckaite S, Gasparovic H, Pavlovic N, Velicki L, Salizzoni S, Wojakowski W, Van Camp G, Nikolic SD, Iung B, Bartunek J, investigators AV-t. Aortic Valve ReplAcemenT versus Conservative Treatment in Asymptomatic SeveRe Aortic Stenosis: The AVATAR trial. *Circulation* 2021.
95. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, Pilgrim T, Petrinic T, Nikolakopoulou A, Salanti G, Sondergaard L, Verma S, Juni P, Windecker S. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of symptomatic severe aortic stenosis: an updated meta-analysis. *Eur Heart J* 2019;**40**(38):3143-3153.

- 1
2
3
4 96. Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P,
5 Lansac E, Rodriguez Munoz D, Rosenhek R, Sjogren J, Tornos Mas P, Vahanian A,
6 Walther T, Wendler O, Windecker S, Zamorano JL, ESC Scientific Document Group.
7 2017 ESC/EACTS Guidelines for the management of valvular heart disease. *Eur Heart J*
8 2017;**38**(36):2739-2791.
9
10 97. Capodanno D, Collet JP, Dangas G, Montalescot G, Ten Berg JM, Windecker S,
11 Angiolillo DJ. Antithrombotic therapy after transcatheter aortic valve replacement. *JACC*
12 *Cardiovasc Interv* 2021;**14**(15):1688-1703.
13
14 98. van der Wulp K, van Wely MH, Rooijackers MJP, Brouwer MA, van den Boogaard M,
15 Pickkers P, Olde Rikkert MGM, Delewi R, Van Mieghem NM, Baan J, Morshuis WJ,
16 van Royen N. Delirium after TAVR: Crosspassing the limit of resilience. *JACC*
17 *Cardiovasc Interv* 2020;**13**(21):2453-2466.
18
19 99. Kilic Y, Smer A, Goldstein N. The importance of palliative care in cardiology:
20 Differences between countries. *J Am Coll Cardiol Case Rep* 2020;**2**:326-329.
21
22 100. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM,
23 Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ. Early palliative care for
24 patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;**363**(8):733-42.
25
26 101. Rogers JG, Patel CB, Mentz RJ, Granger BB, Steinhilber KE, Fiuzat M, Adams PA,
27 Speck A, Johnson KS, Krishnamoorthy A, Yang H, Anstrom KJ, Dodson GC, Taylor
28 DH, Jr., Kirchner JL, Mark DB, O'Connor CM, Tulskey JA. Palliative care in heart failure:
29 The PAL-HF randomized, controlled clinical trial. *J Am Coll Cardiol* 2017;**70**(3):331-
30 341.
31
32 102. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H,
33 Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis
34 D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP,
35 Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M,
36 Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A, ESC Scientific Document
37 Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart
38 failure. *Eur Heart J* 2021;**42**(36):3599-3726.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Table 1: Summary of important clinical trials of primary prevention strategies in older people

Risk factor/ interventions	Clinical trials	Findings
Hypertension	SHEP, ²⁰ Syst-Eur, ²¹ HYVET, ²² SPRINT ^{23, 26} Intensive SBP targets could prevent ~107,500 deaths/y, at the expense of episodes of hypotension (~56,000), syncope (~34,000), serious electrolyte disturbances (~43,000), and acute kidney injury (~88,000) ²⁶	<ul style="list-style-type: none"> • Proven benefit in older people (fit and frail).^{24, 25} Maximum benefits in >75-80 y.²⁵ • Benefits of antihypertensive therapy need to be weighed with risks; increased susceptibility to adverse events in older adults • Treatment targets need to be individualised based on function, frailty, independence to minimise harms^{27, 31}
Dyslipidemia	Age ≥65 y: Meta-analyses suggest benefits ^{33, 35} Limited data >75 y: PROSPER (age 70-82 y), benefits driven by secondary prevention benefit ³⁶	<ul style="list-style-type: none"> • Statins appropriate for most healthy older people for prevention of MI/stroke, less evidence of mortality benefit^{33, 35} • Consider longer time-to-benefit with statins (~2-2.5 years), as well as patient's anticipated life expectancy^{37, 38} • Older people more susceptible to adverse events, and more likely to have co-existing frailty, sarcopenia, polypharmacy; all of which increase potential for harm if adverse effect occurs; thus risk assessment and shared decision making are essential¹⁴
Type 2 diabetes mellitus	Metformin: e.g., UKPDS ⁴² SGLT-2 inhibitors: EMPA-REG OUTCOME, ⁴⁴ DECLARE TIMI-58 ⁴⁵ GLP-1 receptor agonists: SUSTAIN 6, ⁴⁶ REWIND, ⁴⁷ LEADER ⁴⁸	<ul style="list-style-type: none"> • Metformin, SGLT-2 inhibitors, and GLP-1 are recommended for older people for prevention of events⁴³ • Intensive glycemic control not shown to reduce mortality⁴³ • Tailor targets to individual patient – based on function, frailty, life expectancy⁴³

Aspirin	ARRIVE, ⁴⁹ ASCEND, ⁵⁰ ASPREE ^{51, 52}	<ul style="list-style-type: none"> • Minimal or no net clinical benefit in older people (risk of bleeding vs. MACE/mortality)⁴⁹⁻⁵¹ • Not recommended for primary prevention^{14, 54, 55} • Beers Criteria recommends additional caution when using ASA in older adults, due to risk of bleeding⁵⁴
Smoking	Meta-analyses ^{59, 60}	<ul style="list-style-type: none"> • CV risks decreased with time since cessation becoming significant within <5 y, and reach non-smoker level at ~20 y^{59, 60} • Cessation is important at any age¹⁴
Diet	PREDIMED, ⁶¹ EPIC ⁶² Meta-analyses and RCTs suggest no benefit for vitamin C, D, or E Meta-analyses for omega-3 fatty acids conflicting	<ul style="list-style-type: none"> • Mediterranean diet reduced risk of MACE • No apparent benefit of vitamin supplements • Omega-3 fatty acids, particularly EPO may be considered
Exercise	Honolulu Heart Program, ⁶⁹ Zutphen Elderly Study ⁷⁰	<ul style="list-style-type: none"> • Reduction in CVD risk^{14, 69, 70, 73} • Tailor to individual's needs and ability^{14, 73}

CVD; cardiovascular disease; EPO; eicosapentaenoic acid; MACE, major cardiovascular events; SBP, systolic blood pressure. Note abbreviations for trials can be found in the references.

Table 2: Summary of extent of disease indicating a need for revascularization in patients with stable CAD and documented ischaemia or a haemodynamically relevant lesion from the 2018 European guidelines on myocardial revascularization

Goal of improving prognosis
<ul style="list-style-type: none"> • >50% stenosis in <ul style="list-style-type: none"> ○ Left main CAD ○ Proximal left anterior descending CAD ○ 2- or 3-vessel disease with LVEF \leq35% ○ Sole remaining patent coronary artery • Extensive ischaemia on functional testing (>10% LV) or abnormal invasive fractional flow reserve
Goal of improving symptoms
<ul style="list-style-type: none"> • Haemodynamically significant stenosis in patients with limiting angina on optimised medical therapy

Adapted from reference.⁸⁹ CAD, coronary artery disease, LVEF, left ventricular ejection fraction

Table 3: Summary of interventional strategies for patients with aortic stenosis or chronic severe secondary mitral regurgitation from the 2021 European guidelines for valvular heart disease

<p>Recommended indications for intervention in aortic stenosis</p> <ul style="list-style-type: none"> • Symptomatic <ul style="list-style-type: none"> ○ Intervention recommended if severe, high-gradient aortic stenosis (mean gradient ≥ 40 mmHg, $V_{max} \geq 4.0$ m/s and valve area ≤ 1.0 cm²) • Asymptomatic <ul style="list-style-type: none"> ○ Intervention considered if severe and LVEF $< 55\%$, without another cause ○ Intervention considered if LVEF $> 55\%$ with a normal exercise test and any of the following: <ul style="list-style-type: none"> • Very severe (mean gradient ≥ 60 mmHg or $V_{max} \geq 5$ m/s) • Severe valve calcification and V_{max} progression ≥ 0.3 m/s/year • Markedly elevated BNP levels by repeated measurements, without another cause
<p>Recommended mode of intervention (SAVR, TAVI) in patients with aortic stenosis</p> <ul style="list-style-type: none"> • Heart team should assess risks and benefits based on evaluation of clinical, anatomical, and procedural factors, in consultation with informed patient • SAVR recommended in younger patients (< 75 years) at low surgical risk, or patients unsuitable for transfemoral TAVI • TAVI recommended in older patients (≥ 75 years), or in those at high surgical risk • SAVR or TAVI recommended for remaining patients based on clinical, anatomical and procedural factors • Non-transfemoral TAVI considered in patients who are unsuitable for SAVR or transfemoral TAVI
<p>Indications for mitral valve intervention (SAVR, TAVI, TEER) in chronic severe secondary mitral regurgitation (SMR)</p> <ul style="list-style-type: none"> • Surgery/intervention recommended in patients with severe SMR who are symptomatic despite optimal therapy in consultation with heart team • Patients with concomitant CAD or other cardiac disease requiring treatment <ul style="list-style-type: none"> ○ In symptomatic patients. PCI (and/or TAVI) possibly followed by TEER (if persistent severe SMR) considered in those not appropriate for surgery based on assessment by heart team ○ Valve surgery recommended in patients undergoing CABG or other cardiac surgery • Patients without concomitant CAD or other cardiac disease requiring treatment <ul style="list-style-type: none"> ○ In selected symptomatic patients, TEER considered in those not eligible for surgery with a high likelihood of response ○ In selected high-risk symptomatic patients not eligible for surgery and unlikely to respond to TEER, consider a TEER procedure or other trans-catheter valve therapy, after evaluation for ventricular assist device or heart transplant by heart team

Adapted from reference.⁹³

BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; V_{max} , peak transvalvular velocity

Table 3: Summary of interventional strategies for patients with aortic stenosis or chronic severe secondary mitral regurgitation from the 2021 European guidelines for valvular heart disease

<p>Recommended indications for intervention in aortic stenosis</p> <ul style="list-style-type: none"> • Symptomatic <ul style="list-style-type: none"> ○ Intervention recommended if severe, high-gradient aortic stenosis (mean gradient ≥ 40 mmHg, $V_{max} \geq 4.0$ m/s and valve area ≤ 1.0 cm²) • Asymptomatic <ul style="list-style-type: none"> ○ Intervention considered if severe and LVEF $< 55\%$, without another cause ○ Intervention considered if LVEF $> 55\%$ with a normal exercise test and any of the following: <ul style="list-style-type: none"> • Very severe (mean gradient ≥ 60 mmHg or $V_{max} \geq 5$ m/s) • Severe valve calcification and V_{max} progression ≥ 0.3 m/s/year • Markedly elevated BNP levels by repeated measurements, without another cause
<p>Recommended mode of intervention (SAVR, TAVI) in patients with aortic stenosis</p> <ul style="list-style-type: none"> • Heart team should assess risks and benefits based on evaluation of clinical, anatomical, and procedural factors, in consultation with informed patient • SAVR recommended in younger patients (< 75 years) at low surgical risk, or patients unsuitable for transfemoral TAVI • TAVI recommended in older patients (≥ 75 years), or in those at high surgical risk • SAVR or TAVI recommended for remaining patients based on clinical, anatomical and procedural factors • Non-transfemoral TAVI considered in patients who are unsuitable for SAVR or transfemoral TAVI
<p>Indications for mitral valve intervention (SAVR, TAVI, TEER) in chronic severe secondary mitral regurgitation (SMR)</p> <ul style="list-style-type: none"> • Surgery/intervention recommended in patients with severe SMR who are symptomatic despite optimal therapy in consultation with heart team • Patients with concomitant CAD or other cardiac disease requiring treatment <ul style="list-style-type: none"> ○ In symptomatic patients. PCI (and/or TAVI) possibly followed by TEER (if persistent severe SMR) considered in those not appropriate for surgery based on assessment by heart team ○ Valve surgery recommended in patients undergoing CABG or other cardiac surgery • Patients without concomitant CAD or other cardiac disease requiring treatment <ul style="list-style-type: none"> ○ In selected symptomatic patients, TEER considered in those not eligible for surgery with a high likelihood of response ○ In selected high-risk symptomatic patients not eligible for surgery and unlikely to respond to TEER, consider a TEER procedure or other trans-catheter valve therapy, after evaluation for ventricular assist device or heart transplant by heart team

Adapted from reference.⁹³

BNP, B-type natriuretic peptide; CABG, coronary artery bypass grafting; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary intervention; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; V_{max} , peak transvalvular velocity

Table 4: *Considerations for palliative care in patients with advanced HF from the 2021 European guidelines for the management of acute and chronic heart failure*

Indications (despite optimal therapy)
<ul style="list-style-type: none"> • Progressive functional decline and loss of independence • Severe HF symptoms and poor quality of life despite optimal therapy • Frequent episodes of serious decompensation or hospital admissions despite optimal therapy • Not suitable for heart transplantation or mechanical circulatory support • Cardiac cachexia • Close to end of life (clinical assessment)
Key components
<ul style="list-style-type: none"> • Focus on optimising quality of life of the patient and family until death • Frequently assess symptoms (including dyspnoea and pain) and focus on symptom relief • Facilitate access for the patient and family to psychological/spiritual support as needed • Assist with advanced care planning, including preferences around death and resuscitation (may require multidisciplinary team decisions)

Adapted from reference.¹⁰²

